热休克蛋白gp96-肽复合物肿瘤疫苗的应用前景与挑战

Future perspectives and challenges in the development of an antitumor vaccine based on heat shock protein gp96-peptide complex

摘要: 肿瘤组织来源的热休克蛋白gp96-肽复合物（heat shock protein 96-peptide complex，HSPPC-96）结合有肿瘤特异性抗原多肽，能够诱导特异性抗肿瘤免疫。自体HSPPC-96疫苗在延缓肿瘤复发和提高患者总体生存率等方面彰显优势，应用前景广阔。然而作为自体来源的个体化疫苗，HSPPC-96疫苗的实施和推广也面临着巨大的挑战，如肿瘤组织来源限制、对晚期肿瘤疗效不明确等问题。本文综合分析了HSPPC-96疫苗免疫治疗的临床进展、应用前景及其面临的挑战。

Abstract: Tumor-derived heat shock protein-peptide complex 96 (HSPPC-96) containing tumor antigenic peptides can elicit potent tumor-specific and protective immunity. Autologous HSPPC-96 vaccine has been shown to effectively prolong recurrence-free survival and increase the overall survival of many tumors, thereby suggesting extensive future applications. However, as an autologous tumor-derived individual vaccine, the development of HSPPC-96 vaccine is challenged by the lack of an adequate autologous tumor, limited efficacy for advanced-stage cancer, etc. This paper summarized the progress, future perspectives, and challenges in the clinical development of HSPPC-96 vaccine immunotherapy.